Andreas Hochhaus
Andreas Hochhaus is a Professor of Internal Medicine, Hematology and Oncology and interim Head of the Department of Hematology and Medical Oncology at the University Medical Center Jena, in Germany. He was awarded the Endowed Professorship for Leukemia Research from the German José Carreras Leukemia Foundation in 2007.
He has been interested in treatment optimization of chronic myelogenous leukemia (CML) and has been involved in the management of the randomized CML Studies I-IV of the German CML Study Group for more than 19 years. His special interests are the molecular monitoring of minimal residual disease and mechanisms of resistance in CML, and targeted therapy in a variety of neoplastic disorders.
Dr. Hochhaus is investigator for the nilotinib, dasatinib and bosutinib phase II and phase III studies, has been participating in imatinib phase II and III studies and is conducting trials of imatinib combined with pegylated interferon alpha, lonafarnib and everolimus.
He is a member of the European Hematology Association, the American Society of Hematology, the American Society of Clinical Oncology and the International Society of Hematology.
Notes on COVID-19:
"Clinical studies of Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation (RuxCoFlam)".
He has been interested in treatment optimization of chronic myelogenous leukemia (CML) and has been involved in the management of the randomized CML Studies I-IV of the German CML Study Group for more than 19 years. His special interests are the molecular monitoring of minimal residual disease and mechanisms of resistance in CML, and targeted therapy in a variety of neoplastic disorders.
Dr. Hochhaus is investigator for the nilotinib, dasatinib and bosutinib phase II and phase III studies, has been participating in imatinib phase II and III studies and is conducting trials of imatinib combined with pegylated interferon alpha, lonafarnib and everolimus.
He is a member of the European Hematology Association, the American Society of Hematology, the American Society of Clinical Oncology and the International Society of Hematology.
Notes on COVID-19:
"Clinical studies of Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation (RuxCoFlam)".
Country:
Germany